Alchemab Therapeutics Raises £25 Million in Series A Extension
Alchemab Therapeutics, a clinical-stage biotech company, has successfully secured £25 million in a Series A extension funding round, led by the British Business Bank. This significant investment marks the bank's largest commitment to a life sciences firm to date.
Focus on Hard-to-Treat Diseases
Alchemab Therapeutics is at the forefront of developing innovative treatments for challenging diseases. The company utilizes its proprietary Resiliome™ platform, which integrates human biology with artificial intelligence to identify naturally occurring antibodies in individuals who exhibit unusual resistance to certain diseases. This approach aids in the discovery of novel therapeutic candidates.
Leadership and Vision
Dr. Jane Osbourn, the company's Chief Executive Officer, expressed her satisfaction with the investment, stating: "We are delighted that the British Business Bank has recognized the importance of enabling Alchemab to grow and thrive." Under her leadership, Alchemab continues to advance its mission of transforming drug discovery and development.
Strategic Use of Funds
The newly acquired funds will be directed towards expanding Alchemab's clinical pipeline and enhancing its antibody database from 500 million to over 1 billion sequences. This expansion is intended to accelerate the development of additional drug candidates and further validate the company's AI-powered platform.
Recent Achievements
The investment follows the success of Alchemab's first antibody therapy, ATLX-1282, designed for amyotrophic lateral sclerosis (ALS). Currently in clinical development, the therapy has been licensed to Eli Lilly, highlighting the potential of Alchemab's innovative approach.
This funding round brings Alchemab's total Series A funding to a substantial amount, reinforcing its position as a key player in the biotech sector. With continued support from the British Business Bank, Alchemab is well-positioned to make significant strides in the development of new treatments for hard-to-treat diseases.